BACE1 and Alzheimer disease: In addition, the authors documented increased survival of mice treated with the diabody while mice treated with iBsec1 showed no change in total mortality, suggesting that the simultaneous inhibition of BACE-1 and stimulation of the α-secretase processing of APP may be a more advantageous therapeutic approach for AD [65].